Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives $43.17 Consensus Target Price from Analysts

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have been assigned a consensus recommendation of “Buy” from the eight brokerages that are covering the stock, MarketBeat.com reports. Seven research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $43.17.

A number of equities research analysts have recently weighed in on ORKA shares. Stifel Nicolaus assumed coverage on Oruka Therapeutics in a research note on Friday, October 11th. They set a “buy” rating and a $49.00 price target on the stock. Wedbush restated an “outperform” rating and set a $40.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, November 19th. Finally, HC Wainwright reiterated a “buy” rating and set a $45.00 price objective on shares of Oruka Therapeutics in a research note on Friday, December 20th.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $11.44 on Tuesday. Oruka Therapeutics has a 1-year low of $11.32 and a 1-year high of $53.88. The stock has a fifty day simple moving average of $19.10. The firm has a market cap of $400.40 million, a PE ratio of -1.83 and a beta of 0.81.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. acquired a new stake in Oruka Therapeutics during the 4th quarter worth about $144,000. Geode Capital Management LLC acquired a new stake in Oruka Therapeutics during the third quarter worth about $343,000. The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics during the third quarter valued at approximately $1,037,000. Wellington Management Group LLP acquired a new position in Oruka Therapeutics in the third quarter valued at approximately $2,013,000. Finally, Janus Henderson Group PLC purchased a new stake in Oruka Therapeutics in the 3rd quarter worth approximately $5,840,000. 56.44% of the stock is currently owned by institutional investors and hedge funds.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.